Engaging Innovation | Friends of Cancer Research

Engaging Innovation

Featured Post

March 14, 2019

Data Driven: How Oncologists Perceive FDA-Approved Drug Labeling Compared to Other Major Prescribing Resources

Physicians rely on a variety of sources of information to provide high-quality care to patients. In oncology, some of the most prominent resources that inform provider decision-making are the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) clinical practice guidelines; drug compendia; electronic point-of-care decision...
More Posts

Recent Posts

No Results With Current Filter Choices

Real-World Evidence Roundtable

Friends of Cancer Research (Friends) convened a roundtable meeting on February 6, 2019, to identify key challenges and next steps to further characterize how real-world evidence (RWE) can fill evidence gaps about the performance of approved agents used in the real-world setting, including in populations that may not have been...

Designing the Future of Cell Therapies

“Patients are waiting. These therapies are potentially curative. They’re important for the field.” - Ellen Sigal   On May 17, 2019, Friends of Cancer Research (Friends) and the Parker Institute for Cancer Immunotherapy (PICI) held a public meeting on “Designing the Future of Cell Therapies” to explore forward-looking opportunities in the cell...

Friends of Cancer Research Annual Meeting 2018

This year’s Friends of Cancer Research (Friends) Annual Meeting started with a morning keynote by Anna Abram the Deputy Commissioner for Policy, Planning, Legislation and Analysis at the U.S. Food and Drug Administration (FDA). Abram discussed many different initiatives that have been led by Friends over the years including the...

BioPharma Congress IV

On Wednesday, November 14, 2018, Friends of Cancer Research (Friends) and Prevision Policy hosted the fourth annual BioPharma Congress. This year’s event focused on drug pricing, approval standards, patient input, and the future of the U.S. Food & Drug Administration (FDA). Featured speakers included HHS Deputy Secretary Eric Hargan and...

TMB Harmonization Working Group Fall Meeting

On September 13, 2018, Friends of Cancer Research (Friends) reconvened the TMB Harmonization Working Group, which consists of several stakeholders across all health sectors. Building from previous workshops hosted by Friends in the Fall of 2017 and the Spring of 2018, working group members:   Reviewed the findings of the first phase...

22nd Annual Cancer Leadership Awards Reception

This year's awardees at the 22nd Annual Cancer Leadership Awards Reception From L-R: Dr. Anthony Fauci, Dr. Richard Klausner September 21, 2018The Hay-Adams800 16th St NW, Washington, DC 20006   On September 21, 2018, Friends of Cancer Research (Friends) hosted the 22nd Annual Cancer Leadership Awards Reception. The yearly event brings together leaders in...

A Blueprint for Breakthrough: Research and Reimbursement in the Age of Precision Medicine

  Next-generation sequencing (NGS) is becoming a commonly used tool in cancer treatment. Transparency regarding the clinical performance and utility of different NGS-based tests available will aid in clinical decision-making and facilitate improvements in patient care.  The 7th Annual Blueprint for Breakthrough Forum, held by Friends of Cancer Research (Friends) and...
first
prev
1
2
3
4
5
6
next
last
Back to Top